Bandaríkin - enska - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan 4 mg in 4 ml

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - topotecan hydrochloride - solution for infusion - 1mg/1ml

Ísrael - enska - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - powder for solution for infusion - topotecan as hydrochloride 4 mg/vial - topotecan - topotecan - topotecan monotherapy is indicated for the treatment of:• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.• patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease.patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Bandaríkin - enska - NLM (National Library of Medicine)

teva parenteral medicines, inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan injection can cause fetal harm when administered to a pregnant woman. there are no available clinical data on the use of topotecan in pregnancy. to

Bandaríkin - enska - NLM (National Library of Medicine)

cipla usa inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer of the cervix not amenable to curative treatment. topotecan hydrochloride for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride for injection can cause fetal harm when administe

Bandaríkin - enska - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan for injection, as a single agent, is indicated for the treatment of patients with metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. topotecan for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan for injection in combination with cisplatin is indicated for the treatment of patients with stage iv-b, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment. topotecan for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)] . risk summary based on animal data and its mechanism of action, topotecan for injection can cause fetal harm when administered to a pregnant woman. there are no available clinical data on the use o

Bandaríkin - enska - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no av

Kanada - enska - Health Canada

pfizer canada ulc - topotecan (topotecan hydrochloride) - solution - 1mg - topotecan (topotecan hydrochloride) 1mg - antineoplastic agents

Írland - enska - HPRA (Health Products Regulatory Authority)

accord healthcare limited - topotecan (as hydrochloride) - pdr/conc/soln for infus - 4 milligram

Kanada - enska - Health Canada

fresenius kabi canada ltd - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents